GnRHa Trigger in Asian Oocyte Donors- a Dose Finding Study

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

165 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-08-31

Study Completion Date

2015-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of this randomized single center study is to explore the most optimal dose of GnRHa used for triggering of final oocyte maturation in IVF. The study group will consist of oocyte donors who have GnRHa trigger as a standard trigger concept.

Hypothesis: In an Asian oocyte donor population, the use of 0.2 mg, 0.3mg or 0.4 mg of GnRHa will lead to the retrieval of comparable numbers of mature oocytes (MII) and good quality embryos. Moreover, the reproductive outcome in the recipients will be similar regardless of the dose of GnRHa used for trigger.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Gonadotropin-releasing Hormone Antagonist on Triggering Day: A Randomized Controlled Study

NCT00571870

Infertility

COMPLETED NA

Dual Trigger to Reduce Ovarian Hyperstimulation Syndrome

NCT02022228

Infertility and at High Risk of OHSS

UNKNOWN NA

Evaluation of the Optimal Dose of GnRH Agonist for Triggering Final Oocyte Maturation in High Risk OHSS Patients

NCT01973842

Subfertility

UNKNOWN PHASE2

Effect of GnRH Agonist vs GnRH Antagonist on Oocyte Morphology During IVF/ICSI

NCT04724486

In Vitro Fertilization Intracytoplasmic Sperm Injection Infertility

COMPLETED PHASE4

Repeated Injection of GnRH Agonist to Reduce Ovarian Hyperstimulation Syndrome

NCT02022241

Infertility and at High Risk of OHSS

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Methods

A randomized controlled single center study. All oocyte donors, fulfilling the inclusion criteria, will be eligible for inclusion after randomization.

Stimulation, monitoring, oocyte pick-up in donors and embryo transfer in recipients On day two of the cycle, - i.e. prior to commencing stimulation with long acting FSH (Elonva) - donors will be randomized to one of three groups, using different doses of GnRHa (Triptorelin) for trigger. Stimulation will be performed according to the standard stimulation protocol of the clinic, using Elonva followed by co-treatment with a GnRH antagonist from day 5 of stimulation . The dose of Elonva used for stimulation will be either 100 or 150 µg according to the weight of the patient. The first transvaginal ultrasound scan (TVUS) will be performed after seven or eight days after the Elonva depot injection. As soon as two follicles have reached a size of ≥ 17mm, triggering of final oocyte maturation will be performed with one single bolus of Triptorelin, 0.2 mg, 0.3mg or 0.4 mg. The timing of the trigger will be 6 AM for all groups and the oocyte pick-up (OPU) will be performed after 34 hours, according to the usual practice of the clinic. Importantly, each patient will be asked to check the presence of an LH surge via a urine LH detection kit at 4 hours after the trigger bolus has been administered. Embryo transfer will be performed on day two in all recipients.

Study group I Stimulation according to the abovementioned and ovulation trigger with 0.2mg Triptorelin. All other procedures will be performed according to the practice of the clinic.

Study group II Stimulation according to the abovementioned and ovulation trigger with 0.3mg Triptorelin. All other procedures will be performed according to the practice of the clinic.

Study group III Stimulation according to the abovementioned and ovulation trigger with 0.4mg Triptorelin. All other procedures will be performed according to the practice of the clinic.

Randomization Randomization will be performed using sealed envelopes developed via a computer generated list with blocks of twelve. The randomization will be performed on day two of the cycle. Doctors will be blinded to the randomization, but not patients and nurses.

Follicular fluid (FF) collection FF from the first punctured follicle on each side will be collected and cryo-preserved at -20 degrees for subsequent analysis of steroids.

Granulosa cell gene-expression analysis Cumulus and mural granulosa cells will be preserved and snap-frozen from a sub-group of 10 patients in each group. The primary subsequent analysis will focus on possible differences in LHR gene expression according to GnRHa trigger dose.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Normal Oocyte Donors

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

0.2mg Triptorelin

Ovulation trigger with 0.2mg Triptorelin in one subcutaneous injection.

Group Type ACTIVE_COMPARATOR

Triptorelin

Intervention Type DRUG

Triptorelin is given by s.c injection for ovulation triggering.

0.3mg Triptorelin

Ovulation trigger with 0.3mg Triptorelin in one subcutaneous injection.

Group Type ACTIVE_COMPARATOR

Triptorelin

Intervention Type DRUG

Triptorelin is given by s.c injection for ovulation triggering.

Active Comparator: 0.4mg Triptorelin

Ovulation trigger with 0.4mg Triptorelin in one subcutaneous injection.

Group Type ACTIVE_COMPARATOR

Triptorelin

Intervention Type DRUG

Triptorelin is given by s.c injection for ovulation triggering.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Triptorelin

Triptorelin is given by s.c injection for ovulation triggering.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Diphereline 0.1 mg powder and solvent

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Oocyte donors who meet the following criteria:

* Age 18 - 35
* BMI \< 28kg/m2
* Normal ovarian reserve, defined by AMH \> 1.25 ng/ml or AFC ≥ 6 measured within two months prior to stimulation start
* Receiving GnRH-antagonist protocol for ovarian stimulation,
* Agreement to participate in the study, and to disclose any medical events to the investigator. The subject must be willing and able to comply with the protocol requirements for the duration of the study.
* Have given written informed consent with the understanding that the subject may withdraw consent at any time without prejudice to future medical care.

Exclusion Criteria

* Previous poor response (≤ 3 oocytes) after high dose FSH stimulation
* Chronical medical conditions like Diabetes, Crohns disease, Thyroid disease, Hepatitis B and Sexually Transmitted Diseases Simultaneous participation in an interventional clinical trial.
* Concommitant use of either LH or hMG/uFSH preparations in study cycle

Minimum Eligible Age

18 Years

Maximum Eligible Age

35 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No